JPS62155284A - 生理活性物質ｋ−２５２の誘導体 - Google Patents

生理活性物質ｋ−２５２の誘導体

Info

Publication number
JPS62155284A
JPS62155284A JP29517285A JP29517285A JPS62155284A JP S62155284 A JPS62155284 A JP S62155284A JP 29517285 A JP29517285 A JP 29517285A JP 29517285 A JP29517285 A JP 29517285A JP S62155284 A JPS62155284 A JP S62155284A
Authority
JP
Japan
Prior art keywords
compound
formula
lower alkyl
aralkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP29517285A
Other languages
English (en)
Japanese (ja)
Other versions
JPH051794B2 (cs
Inventor
Tadashi Hirata
平田　正
Mitsuru Takahashi
充 高橋
Tsutomu Muragata
力 村形
Hiroshi Kase
廣 加瀬
Koji Yamada
耕二 山田
Kazuyuki Iwahashi
和幸 岩橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP29517285A priority Critical patent/JPS62155284A/ja
Publication of JPS62155284A publication Critical patent/JPS62155284A/ja
Publication of JPH051794B2 publication Critical patent/JPH051794B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP29517285A 1985-12-27 1985-12-27 生理活性物質ｋ−２５２の誘導体 Granted JPS62155284A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP29517285A JPS62155284A (ja) 1985-12-27 1985-12-27 生理活性物質ｋ−２５２の誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29517285A JPS62155284A (ja) 1985-12-27 1985-12-27 生理活性物質ｋ−２５２の誘導体

Publications (2)

Publication Number Publication Date
JPS62155284A true JPS62155284A (ja) 1987-07-10
JPH051794B2 JPH051794B2 (cs) 1993-01-11

Family

ID=17817161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP29517285A Granted JPS62155284A (ja) 1985-12-27 1985-12-27 生理活性物質ｋ−２５２の誘導体

Country Status (1)

Country Link
JP (1) JPS62155284A (cs)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877776A (en) * 1987-12-24 1989-10-31 Kyowa Hakko Kogyo Co., Ltd. K-252 compounds
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
WO1994004541A3 (en) * 1992-08-12 1994-06-09 Upjohn Co Protein kinase inhibitors and related compounds combined with taxol
WO1994016706A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1996001263A1 (en) * 1994-07-04 1996-01-18 Kyowa Hakko Kogyo Co., Ltd. Process for producing indolocarbazole derivative
WO1996013506A1 (en) * 1994-10-26 1996-05-09 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5516771A (en) * 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5674867A (en) * 1992-09-21 1997-10-07 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production
US6093713A (en) * 1997-12-31 2000-07-25 Kyowa, Hakko, Kogyo Co., Ltd. 3'-epimeric K-252A derivatives
US6184217B1 (en) 1996-06-25 2001-02-06 Cephalon, Inc. Use of K-252a derivative
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US6306849B1 (en) 1996-06-03 2001-10-23 Cephalon, Inc. Selected derivatives of K-252a
US6472385B1 (en) 1999-08-09 2002-10-29 Trustees Of Darmouth College Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
WO2006010628A1 (en) * 2004-07-29 2006-02-02 Creabilis Therapeutics S.P.A. Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies
EP2098230A1 (en) 1997-03-31 2009-09-09 Boston Scientific Scimed Limited Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP2292225A1 (en) 1997-03-31 2011-03-09 Boston Scientific Scimed Limited Dosage form comprising taxol in crystalline form

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US4877776A (en) * 1987-12-24 1989-10-31 Kyowa Hakko Kogyo Co., Ltd. K-252 compounds
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
AU675236B2 (en) * 1992-07-24 1997-01-30 Cephalon, Inc. Bis-staurosporine and K-252a derivatives
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5741808A (en) * 1992-07-24 1998-04-21 Cephalon, Inc. Protein kinase inhibitors for treatmen of neurological disorders
WO1994004541A3 (en) * 1992-08-12 1994-06-09 Upjohn Co Protein kinase inhibitors and related compounds combined with taxol
US5674867A (en) * 1992-09-21 1997-10-07 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production
EP2324829A1 (en) 1993-01-28 2011-05-25 Boston Scientific Limited Therapeutic inhibitors of vascular smooth muscle cells
EP2298310A2 (en) 1993-01-28 2011-03-23 Boston Scientific Limited Therapeutic inhibitors of vascular smooth muscle cells
WO1994016706A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US5516771A (en) * 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5654427A (en) * 1993-05-28 1997-08-05 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives to treat a pathological condition of the prostate
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5585488A (en) * 1994-07-04 1996-12-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing indolocarbazole derivatives
WO1996001263A1 (en) * 1994-07-04 1996-01-18 Kyowa Hakko Kogyo Co., Ltd. Process for producing indolocarbazole derivative
EP1125938A1 (en) * 1994-10-26 2001-08-22 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
WO1996013506A1 (en) * 1994-10-26 1996-05-09 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US6306849B1 (en) 1996-06-03 2001-10-23 Cephalon, Inc. Selected derivatives of K-252a
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
US6184217B1 (en) 1996-06-25 2001-02-06 Cephalon, Inc. Use of K-252a derivative
EP2098230A1 (en) 1997-03-31 2009-09-09 Boston Scientific Scimed Limited Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
EP2292225A1 (en) 1997-03-31 2011-03-09 Boston Scientific Scimed Limited Dosage form comprising taxol in crystalline form
US6451786B1 (en) 1997-12-31 2002-09-17 Cephalon, Inc. 3′-epimeric k-252a derivatives
US6093713A (en) * 1997-12-31 2000-07-25 Kyowa, Hakko, Kogyo Co., Ltd. 3'-epimeric K-252A derivatives
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6472385B1 (en) 1999-08-09 2002-10-29 Trustees Of Darmouth College Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
WO2006010628A1 (en) * 2004-07-29 2006-02-02 Creabilis Therapeutics S.P.A. Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies

Also Published As

Publication number Publication date
JPH051794B2 (cs) 1993-01-11

Similar Documents

Publication Publication Date Title
JPS62155284A (ja) 生理活性物質ｋ−２５２の誘導体
AU2020241258A1 (en) Novel small molecule inhibitors of tead transcription factors
AU2013371146A1 (en) 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
KR19990063987A (ko) 신규 헤테로시클릭 유도체 및 이것의 의약 용도
JP5583698B2 (ja) プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
KR102305710B1 (ko) Gpr84 수용체 길항제 및 이의 용도
JPS63225374A (ja) チアゾ−ル誘導体、その製造法およびその組成物
CN105254635A (zh) 一类咪唑并吡嗪类化合物及其药物组合物和用途
EP1012147A2 (en) O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
CN103450176B (zh) 一类含2-（4-氨基苯基）苯并噻唑萘酰亚胺化合物及其应用
JPS62155285A (ja) 生理活性物質ｋ−２５２の誘導体
CN118772143A (zh) 一种具有双靶点的双功能铁死亡诱导剂及其制备方法和应用
JP2674199B2 (ja) 二環式アミン化合物およびその製造法
CN115677691B (zh) 一种苯并萘啶酰胺抗癌药sn28049及其类似物的制备方法
JP5704784B2 (ja) 磁気共鳴画像法用造影剤
CN103553957B (zh) 含有组蛋白去乙酰化酶抑制活性的秋水仙碱衍生物及制备方法和用途
BR0013750B1 (pt) Intermediários para a produção de derivados de ácido naftiridina-3-carboxílico
CN104961725B (zh) 4‑α,β不饱和酰胺基喹啉类化合物及制备和应用
FI62531C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbart 3-yan-n-(n n-dimetylamino-propyl)-iminodibensyl och syraadd itonssalter daerav
FI60561B (fi) Foerfarande foer framstaellning av antiinflammatoriska 6,7-dimetoxi-1,2,3,4-tetrahydro-1-isokinolinacetami-dderivat
DK155280B (da) Analogifremgangsmaade til fremstilling af indolderivater
JP3760484B2 (ja) チエノ［２，３−ｄ］ピリミジン−４−オン誘導体
CN113480536B (zh) 螺环哌啶酮类衍生物
Minarini et al. Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1, 2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics
CN111560013B (zh) 一种自噬抑制剂及其应用

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term